Our top pick for
Scully Royalty Ltd is a capital markets business based in the US. Scully Royalty shares (SRL) are listed on the NYSE and all prices are listed in US Dollars. Scully Royalty employs 81 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.07|
|52-week range||$3.71 - $16.35|
|50-day moving average||$11.46|
|200-day moving average||$12.30|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-3.32%|
|1 month (2021-09-20)||-0.72%|
|3 months (2021-07-20)||-27.27%|
|6 months (2021-04-20)||35.83%|
|1 year (2020-10-20)||156.84%|
|2 years (2019-10-18)||6.61%|
|3 years (2018-10-19)||107.69%|
|5 years (2016-10-20)||422.17%|
Valuing Scully Royalty stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Scully Royalty's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Scully Royalty's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 513x. In other words, Scully Royalty shares trade at around 513x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||$60.7 million|
|Operating margin TTM||21.65%|
|Gross profit TTM||$13.1 million|
|Return on assets TTM||0.04%|
|Return on equity TTM||0.06%|
|Market capitalisation||$154.5 million|
TTM: trailing 12 months
There are currently 2,266 Scully Royalty shares held short by investors – that's known as Scully Royalty's "short interest". This figure is 49.9% up from 1,512 last month.
There are a few different ways that this level of interest in shorting Scully Royalty shares can be evaluated.
Scully Royalty's "short interest ratio" (SIR) is the quantity of Scully Royalty shares currently shorted divided by the average quantity of Scully Royalty shares traded daily (recently around 10300). Scully Royalty's SIR currently stands at 0.22. In other words for every 100,000 Scully Royalty shares traded daily on the market, roughly 220 shares are currently held short.
However Scully Royalty's short interest can also be evaluated against the total number of Scully Royalty shares, or, against the total number of tradable Scully Royalty shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Scully Royalty's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Scully Royalty shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable Scully Royalty shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Scully Royalty.
Find out more about how you can short Scully Royalty stock.
We're not expecting Scully Royalty to pay a dividend over the next 12 months.
Scully Royalty's shares were split on a 108:100 basis on 11 November 2021. So if you had owned 100 shares the day before before the split, the next day you'd have owned 108 shares. This wouldn't directly have changed the overall worth of your Scully Royalty shares – just the quantity. However, indirectly, the new 7.4% lower share price could have impacted the market appetite for Scully Royalty shares which in turn could have impacted Scully Royalty's share price.
Over the last 12 months, Scully Royalty's shares have ranged in value from as little as $3.71 up to $16.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Scully Royalty's is 1.4603. This would suggest that Scully Royalty's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Scully Royalty Ltd. operates as an iron ore mining company in the Americas, Africa, Canada, Asia, and Europe. The company holds royalty interest in the Scully iron ore mine located in the Province of Newfoundland and Labrador, Canada. It also engages in manufacturing, and medical supplies and services industries. The company was formerly known as MFC Bancorp Ltd. and changed its name to Scully Royalty Ltd. in June 2019.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.